on the use of CD22-specific CAR-T therapy in 21 patients with high-risk r/r LBCL and DLBCL after CD19-targeted CAR-T therapy failure, high rates of both overall objective response and complete remission were demonstrated, which were 86% and 61%, respectively (93). Here, CD19 is linked to diffuse large B-cell lymphoma.